Literature DB >> 33078908

Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.

Heba Alwan1, Stefano La Rosa2, Peter Andreas Kopp3,4, Simon Germann1, Manuela Maspoli-Conconi5, Christine Sempoux2, Jean-Luc Bulliard1,5.   

Abstract

The incidence of neuroendocrine neoplasms (NENs) seems to increase worldwide. Long-term, population-based series that consider tumor differentiation are, however, sparse. We assessed the incidence trend of lung and gastroenteropancreatic (GEP) NENs according to the latest International Agency for Research on Cancer/World Health Organization classification over a 41-year time period in two Swiss regions. All cases of lung and GEP NENs recorded in the Vaud and Neuchâtel Cancer Registries from 1976 to 2016 were included. NENs were stratified into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Changes in annual age-standardized incidence rates were calculated for lung and GEP NETs and NECs by sex. Of 4,141 patients diagnosed with NENs, 65% were men. The incidence of lung NETs among men and women increased by 3.9%/year (95% CI: -5.3, 14.1%) and 4.9%/year (0.1, 9.9%), respectively, between 1976 and 2016. The incidence of lung NECs decreased by 2.6%/year (-3.1,-1.8%) in men from 1985 to 2016 whereas it increased in women between 1976 and 1998 by 6%/year (4.2, 7.9%). For GEP NETs, a steady annual increase in incidence occurred between 1976 and 2016 with a magnitude of 1.7% (0.7, 2.7%) in men and 1.3% (0.5, 2.1%) in women. No significant trend in incidence of GEP NECs was found for both sexes. The incidence trends of lung NECs in men and women parallel changes in smoking prevalence in the population. Causes of the increase in incidence of GEP NETs are likely multifactorial. Our study supports the importance of evaluating the epidemiology of NENs by tumor differentiation.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Switzerland; epidemiology; incidence; neuroendocrine neoplasms; trend

Mesh:

Year:  2020        PMID: 33078908      PMCID: PMC7774736          DOI: 10.1002/cam4.3524

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  26 in total

Review 1.  Neuroendocrine tumors of the lung: an update.

Authors:  Natasha Rekhtman
Journal:  Arch Pathol Lab Med       Date:  2010-11       Impact factor: 5.534

2.  Evaluation of completeness of case ascertainment in Swiss cancer registration.

Authors:  Matthias Lorez; Andrea Bordoni; Christine Bouchardy; Jean-Luc Bulliard; Bertrand Camey; Silvia Dehler; Harald Frick; Isabelle Konzelmann; Manuela Maspoli; Seyed M Mousavi; Sabine Rohrmann; Volker Arndt
Journal:  Eur J Cancer Prev       Date:  2017-09       Impact factor: 2.497

3.  Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry.

Authors:  Adele Caldarella; Emanuele Crocetti; Eugenio Paci
Journal:  Pathol Oncol Res       Date:  2011-04-09       Impact factor: 3.201

4.  Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.

Authors:  Daniel M Halperin; Chan Shen; Arvind Dasari; Ying Xu; Yiyi Chu; Shouhao Zhou; Ya-Chen Tina Shih; James C Yao
Journal:  Lancet Oncol       Date:  2017-02-24       Impact factor: 41.316

Review 5.  Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.

Authors:  M Fraenkel; M Kim; A Faggiano; W W de Herder; G D Valk
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark.

Authors:  Halla Skuladottir; Fred R Hirsch; Heine H Hansen; Jørgen H Olsen
Journal:  Lung Cancer       Date:  2002-08       Impact factor: 5.705

8.  Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010.

Authors:  Raziye Boyar Cetinkaya; Bjarte Aagnes; Espen Thiis-Evensen; Steinar Tretli; Deidi S Bergestuen; Svein Hansen
Journal:  Neuroendocrinology       Date:  2015-11-13       Impact factor: 4.914

9.  Changes in the Epidemiology of Neuroendocrine Tumours.

Authors:  Isabel Huguet; Ashley B Grossman; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2015-10-28       Impact factor: 4.914

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more
  1 in total

Review 1.  Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?

Authors:  Jack Cope; Raj Srirajaskanthan
Journal:  Curr Oncol Rep       Date:  2022-01-27       Impact factor: 5.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.